Kodiak Sciences, Inc. (KOD)

Kodiak Sciences' stock price has been impacted by several events over the past six months. The company closed an upsized public offering of common stock in December 2025. New data from the Phase 1b APEX study for KSI-101 was presented in September 2025 and February 2026. Kodiak Sciences reported its Q3 2025 results in November 2025. The company participated in the J.P. Morgan Healthcare Conference in January 2026. Positive topline results from the GLOW2 Phase 3 study for Zenkuda in diabetic retinopathy were announced in March 2026, leading to a share price surge and accelerated BLA submission plans. Kodiak Sciences also reported its Fourth Quarter and Full Year 2025 Financial Results in March 2026. KOD's share price has experienced volatility, with a notable increase of 1,927.18% between April 8, 2025, and April 7, 2026.

There is no inherent demand seasonality for Kodiak Sciences' products, as demand for retinal disease therapies is generally consistent throughout the year, driven by disease prevalence rather than seasonal factors.

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for retinal diseases, leveraging its Antibody Biopolymer Conjugate (ABC) Platform. Its pipeline includes Tarcocimab tedromer (Zenkuda / KSI-301) for retinal vascular diseases, KSI-501 for retinal vascular diseases with inflammation, and KSI-101 for macular edema secondary to inflammation (MESI).

Kodiak Sciences Inc. is headquartered in Palo Alto, California, United States. The company aims to enhance its presence in North American and European markets and explore global product launch opportunities.

Kodiak Sciences' brand reputation has been positively influenced by the robust positive topline results from the Phase 3 GLOW2 study of Zenkuda in diabetic retinopathy, leading to a stock price increase and accelerated BLA submission plans. This has bolstered confidence in the drug's commercial prospects and the company's scientific platform.

Kodiak Sciences Inc. has significant institutional ownership, with 159 institutional owners holding 55,534,346 shares as of April 9, 2026. Major institutional owners include Baker Bros. Advisors Lp, BlackRock, Inc., and Vanguard Group Inc. Individual ownership accounts for approximately 4.78% of the company's shares, with key insiders including Dr. Victor Perlroth and Dr. Richard S. Levy.